Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02693418 · ClinicalTrials.gov registry record · Phase 1

Duration of Effect of Acidform Gel on Vaginal pH

A Phase 1 study, sponsored by Evofem.

Completed
Registry status
Phase 1
Development phase
105
Enrollment target

NCT02693418: Completed Phase 1 study, sponsored by Evofem.

NCT02693418 is a Phase 1 study that has completed, run by Evofem. The registered enrollment target is 105 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02693418, a Phase 1 study, has completed, sponsored by Evofem.

COMPLETED
Registry status
Phase 1
Development phase
105 participants
Enrollment target

Study Summary

The objective of this study was to determine the magnitude and duration of the reduction in pH (acidification) following a single dose of Acidform vaginal gel containing 3, 4, or 5 g compared with hydroxyethylcellulose placebo gel (4 g) or no treatment. Vaginal pH was measured 1 h, 6 h, 12 h, 24 h, then once daily for 7 days. In addition, the participants were assessed for an exploratory endpoint to the determine effect of one dose of Acidform gel (3, 4 or 5 g) or placebo gel (4 g) or no treatment, on asymptomatic bacterial vaginosis (BV).

Primary Outcome

Vaginal swabs were used to collect samples from the vagina of women dosed with Acidform, HEC placebo, or no treatment. The pH of the samples was measured at pre-determined time points over the course of 7 days.

Interventions

  • DRUG Acidform 5 g
  • DRUG Placebo 4 g
  • DRUG Acidform 4 g
  • DRUG Acidform 3 g

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2016-08-24
Est. Completion 2016-12-12
Phase Phase 1
Evofem

6 total trials

What the finished NCT02693418 record still lists

NCT02693418 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher).

The record links to 0 conditions, and to 4 interventions - of which Acidform 5 g is the first listed.

NCT02693418 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02693418 about?

NCT02693418 is a clinical study titled "Duration of Effect of Acidform Gel on Vaginal pH". The objective of this study was to determine the magnitude and duration of the reduction in pH (acidification) following a single dose of Acidform vaginal gel containing 3, 4, or 5 g compared with hydroxyethylcellulose placebo gel (4 g) or no treatment. Vaginal pH was measured 1 h, 6 h, 12 h, 24 h, ...

What is the current status of trial NCT02693418?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2016-08-24. Estimated completion is 2016-12-12.

What interventions are being tested in trial NCT02693418?

The interventions under investigation include: Acidform 5 g (DRUG), Placebo 4 g (DRUG), Acidform 4 g (DRUG), Acidform 3 g (DRUG).

Who is sponsoring clinical trial NCT02693418?

This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02693418's enrollment target sits among peer trials

105 533rd of 2000 higher than 1,465 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02693418, the US trial registry maintained by the National Library of Medicine. NCT02693418 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.